- Home
- TWN vs IMMP Comparison
TWN vs IMMP Comparison
Compare TWN & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWN
- IMMP
- Stock Information
- Founded
- TWN 1986
- IMMP 1987
- Country
- TWN Hong Kong
- IMMP Australia
- Employees
- TWN N/A
- IMMP N/A
- Industry
- TWN Trusts Except Educational Religious and Charitable
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- TWN Finance
- IMMP Health Care
- Exchange
- TWN Nasdaq
- IMMP Nasdaq
- Market Cap
- TWN 306.6M
- IMMP 304.0M
- IPO Year
- TWN N/A
- IMMP N/A
- Fundamental
- Price
- TWN $46.92
- IMMP $2.18
- Analyst Decision
- TWN
- IMMP Buy
- Analyst Count
- TWN 0
- IMMP 2
- Target Price
- TWN N/A
- IMMP $8.50
- AVG Volume (30 Days)
- TWN 20.1K
- IMMP 147.2K
- Earning Date
- TWN 01-01-0001
- IMMP 12-27-2024
- Dividend Yield
- TWN 1.10%
- IMMP N/A
- EPS Growth
- TWN N/A
- IMMP N/A
- EPS
- TWN N/A
- IMMP N/A
- Revenue
- TWN N/A
- IMMP $2,563,302.00
- Revenue This Year
- TWN N/A
- IMMP N/A
- Revenue Next Year
- TWN N/A
- IMMP $10.84
- P/E Ratio
- TWN N/A
- IMMP N/A
- Revenue Growth
- TWN N/A
- IMMP 9.59
- 52 Week Low
- TWN $25.22
- IMMP $1.66
- 52 Week High
- TWN $41.51
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- TWN 70.80
- IMMP 57.46
- Support Level
- TWN $44.67
- IMMP $2.00
- Resistance Level
- TWN $47.01
- IMMP $2.39
- Average True Range (ATR)
- TWN 1.15
- IMMP 0.12
- MACD
- TWN 0.33
- IMMP 0.01
- Stochastic Oscillator
- TWN 100.00
- IMMP 66.67
About TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.